


Supplemental Table 1: SNPs showing nominally significant differences between PD cases vs controls in *GBA1* carriers and non-carriers.

Study	Group	rs ID	Fisher-exact test p-value	FDR-corrected p-value
UK Biobank	Noncarriers	rs11158026	2.20e-06	8.58e-05
		rs356182	1.49e-05	2.90e-04
		rs1474055	3.34e-04	3.31e-03
		rs11724635	3.40e-04	3.31e-03
		rs17649553	1.03e-03	6.89e-03
		rs34311866	1.06e-03	6.89e-03
		rs14235	2.92e-03	1.63e-02
		rs117896735	9.55e-03	4.55e-02
	<i>GBA1</i> -carriers	rs1474055	0.0112	0.179
		rs601999	0.0118	0.179
		rs356182	0.0138	0.179
		rs6430538	0.0197	0.192
LuxPark	Noncarriers	rs34311866	0.001152859	0.04726723
	<i>GBA1</i> -carriers	rs1555399	0.003984293	0.1633560

Supplemental Figure 1: Parkinson's disease risk stratified by polygenic risk scores categories and the status and severity of rare pathogenic *GBA1* variants in UK Biobank (A), LuxPark (B)

A)



B)

